40.16

1.03% 0.41

After Hours: 40.16

Vera Therapeutics Inc (VERA)

Overview News Price History Option Chain Financials Discussions Forecast

Vera Therapeutics Inc stock is traded at $40.16, with a volume of 1.41M. It is up +1.03% in the last 24 hours and down -3.65% over the past month. Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Previous Close:

$39.75

Open:

$40.38

24h Volume:

1.41M

Relative Volume:

1.23

Market Cap:

$2.87B

Revenue:

Net Income/Loss:

$-299.62M

P/E Ratio:

-8.6108

EPS:

-4.6639

Net Cash Flow:

$-241.73M

1W Performance:

+4.80%

1M Performance:

-3.65%

6M Performance:

+48.96%

1Y Performance:

+49.02%

1-Day Range:

$39.83

$41.55

1-Week Range:

$37.51

$42.25

52-Week Range:

$18.53

$56.05

Vera Therapeutics Inc Stock (VERA) Company Profile

Name

Vera Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

650-770-0077

Address

2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE

Employee

249

Twitter

Next Earnings Date

2024-08-08

Latest SEC Filings

VERA's Discussions on Twitter

Compare VERA vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VERA Vera Therapeutics Inc	40.16	2.84B	0	-299.62M	-241.73M	-4.6639
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Oct-16-25	Initiated	BofA Securities	Buy
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy
Feb-04-25	Initiated	Wolfe Research	Outperform
Jan-28-25	Initiated	Goldman	Buy
Nov-21-24	Initiated	Wells Fargo	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform
Nov-10-23	Upgrade	Jefferies	Hold → Buy
Aug-16-23	Initiated	Guggenheim	Buy
Jan-04-23	Downgrade	Jefferies	Buy → Hold
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral
Jul-12-22	Initiated	JP Morgan	Overweight
May-02-22	Initiated	H.C. Wainwright	Buy
Apr-19-22	Initiated	Wedbush	Outperform

View All

Vera Therapeutics Inc Stock (VERA) Latest News

04:56 AM

Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360

04:56 AM

08:13 AM

Vera Therapeutics names Jane Wright-Mitchell as chief legal officer By Investing.com - Investing.com Canada

08:13 AM

07:41 AM

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer - Quiver Quantitative

07:41 AM

07:30 AM

Biotech nearing drug launch hires veteran lawyer as legal chief - Stock Titan

07:30 AM

04:21 AM

E. Ohman J or Asset Management AB Invests $2 Million in Vera Therapeutics, Inc. $VERA - MarketBeat

04:21 AM

Mar 24, 2026

Vera Therapeutics stock advances on promising Phase 3 data for atacicept in IgA nephropathy, boostin - AD HOC NEWS

Mar 24, 2026

Mar 22, 2026

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 22, 2026

(VERA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Mar 22, 2026

Mar 20, 2026

Investment Firm Boosts Vera Therapeutics Holding to $41.75M in 2026News and Statistics - IndexBox

Mar 20, 2026

This $91 Million Investment Reflects Strong Confidence in a Biotech Firm Awaiting an FDA Ruling This Year - Bitget

Mar 20, 2026

Hudson Bay Capital Management Boosts Stake in Vera Therapeutics - National Today

Mar 20, 2026

Hudson Bay Capital Management LP Raises Holdings in Vera Therapeutics, Inc. $VERA - MarketBeat

Mar 20, 2026

Mar 19, 2026

Why Vera Therapeutics Stock Is Suddenly Taking Off - TipRanks

Mar 19, 2026

Mar 18, 2026

Volume Summary: What is the next catalyst for Vera Therapeutics Inc2026 Top Decliners & Weekly Setup with High ROI Potential - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Deep Track Capital, LP Increases Stake in Vera Therapeutics Inc - GuruFocus

Mar 17, 2026

Algert Global LLC Acquires 39,235 Shares of Vera Therapeutics, Inc. $VERA - MarketBeat

Mar 17, 2026

Mar 16, 2026

Vera Therapeutics (VERA) finance chief exercises options for 10,000 shares - Stock Titan

Mar 16, 2026

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment - AOL.com

Mar 16, 2026

Eversept Partners Increases Stake in Vera Therapeutics - Intellectia AI

Mar 16, 2026

Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears - simplywall.st

Mar 16, 2026

HighVista Strategies LLC Increases Position in Vera Therapeutics, Inc. $VERA - MarketBeat

Mar 16, 2026